The GLP-1 Gold Rush: Why Morgan Stanley Just Downgraded Novo Nordisk Amid Fierce Competition

Global Markets Rebound: Asian Shares Climb After Wall Street Ends Downturn

Unmasking the Hidden Health Crisis: Why 'Thin-Fat' Indians Redefine Obesity and the Promise of GLP-1 Drugs

Eli Lilly's Groundbreaking Oral Weight-Loss Pill Set to Transform India's Obesity Battle

Eli Lilly Declares UK 'Worst in Europe' for Drug Prices, Threatening Patient Access to New Medicines

Celltrion Fortifies Biologics Dominance with Strategic Eli Lilly Plant Acquisition

South Korean Pharma Giant Celltrion Seals $330M Deal for Eli Lilly's U.S. Biologics Facility

The Race for the Next Weight Loss Breakthrough: Chinese Biotechs Challenge Global Giants

Game-Changer: New Ozempic-Like Pill Achieves Remarkable 13% Weight Loss in Landmark Study

Pfizer's Bold Gambit: Unlocking the Future of Obesity Treatment with Metsera and Oral GLP-1s

Orforglipron: The Oral Weight-Loss Revolution – Promise or Peril?

Lilly's Groundbreaking Weight-Loss Pill Shows Promising Early Results, But The Journey Continues

FDA Steps In: Big Pharma's Weight-Loss Claims Under Scrutiny After Oprah Video

Virginia Lands Groundbreaking $5 Billion Eli Lilly Investment: A Quantum Leap for Cancer Medicine

Eli Lilly Unveils $5 Billion Manufacturing Marvel in Virginia, Set to Revolutionize Healthcare and Spark Economic Boom

Proceed with Caution: 14 High-Flying Stocks Now Deemed Overvalued by Morningstar

The Next Battleground: Novo Nordisk and Eli Lilly's Hundred-Year War for Oral GLP-1 Dominance

The Next Frontier: Eli Lilly and Novo Nordisk Gear Up for a Revolution in Oral Obesity Treatment

Legal Setback: Eli Lilly's Appeal Fails, $1.8 Billion Medicaid Fraud Award Upheld

The Ozempic Effect: How Weight-Loss Drugs Are Reshaping Economies and Creating Thousands of Jobs

The Weight of Success: Why Breakthrough Obesity Drugs Are a Budget Breaker

The Cost-Benefit Revolution: GLP-1 Drugs Deemed Value-Packed, But Price Tags Loom Large

Eli Lilly Unveils TuneLab: Revolutionizing Biotech with AI-Powered Drug Discovery

Eli Lilly Unleashes AI Powerhouse for Revolutionary Drug Discovery

Eli Lilly Unleashes AI Powerhouse: A New Era for Rapid Drug Discovery

A New Era in Health: WHO Adds Mounjaro and Ozempic to Essential Medicines List

Unleashed: Jim Cramer's Ultimate Fantasy Stock Portfolio Revealed!

A New Horizon in Lung Cancer Treatment: FDA Grants Breakthrough Status to Lilly-Merck Combination Therapy

Wegovy Triumphs: Novo Nordisk's Obesity Drug Significantly Cuts Heart Attack and Stroke Risk, Setting a New Benchmark in Cardiovascular Protection

UK Healthcare on Edge: Mounjaro Shortages Loom as Eli Lilly's Price Hike Sparks Patient Panic

The Weighty Truth: Are Next-Gen Obesity Drugs Worth Their Premium Price Tag?

Viking Therapeutics' Oral Weight Loss Drug Stumbles: VK2735 Data Leaves Investors Underwhelmed